Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
05 Diciembre 2023 - 9:52PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that a conference call and webcast
will be held with executives from Arvinas and Pfizer Inc. (NYSE:
PFE) to discuss vepdegestrant (ARV-471) data presented at the 2023
San Antonio Breast Cancer Symposium (SABCS) as well as plans to
expand the vepdegestrant development program.
Investor Call & Webcast DetailsArvinas will
host a conference call and webcast on Wednesday, December 6 at 7:30
a.m. ET to discuss these updates. Participants are invited to
listen by going to the Events and Presentation section under the
Investors page on the Arvinas website at www.arvinas.com. A
replay of the webcast will be archived on the Arvinas website
following the presentation.
About vepdegestrant (ARV-471)Vepdegestrant is
an investigational, orally bioavailable PROTAC protein degrader
designed to specifically target and degrade the estrogen receptor
(ER) for the treatment of patients with ER positive (ER+)/human
epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-)
breast cancer.
In preclinical studies, vepdegestrant demonstrated up to 97% ER
degradation in tumor cells, induced robust tumor shrinkage when
dosed as a single agent in multiple ER-driven xenograft models, and
showed increased anti-tumor activity when compared to a standard of
care agent, fulvestrant, both as a single agent and in combination
with a CDK4/6 inhibitor. In July 2021, Arvinas announced a global
collaboration with Pfizer for the co-development and
co-commercialization of vepdegestrant; Arvinas and Pfizer will
equally share worldwide development costs, commercialization
expenses, and profits. Ongoing and planned clinical trials will
continue to monitor and evaluate the safety and anti-tumor activity
of vepdegestrant.
About ArvinasArvinas is a clinical-stage
biotechnology company dedicated to improving the lives of patients
suffering from debilitating and life-threatening diseases through
the discovery, development, and commercialization of therapies that
degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC Discovery Engine platform to engineer proteolysis targeting
chimeras, or PROTAC targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. In addition to its robust preclinical pipeline of PROTAC
protein degraders against validated and “undruggable” targets, the
company has three investigational clinical-stage programs: ARV-766
and bavdegalutamide for the treatment of men with metastatic
castration-resistant prostate cancer; and vepdegestrant (ARV-471)
for the treatment of patients with locally advanced or metastatic
ER+/HER2- breast cancer. Arvinas, as part of its overall business
strategy, selectively assesses opportunities for potential
collaboration, license, marketing and royalty arrangements, and
similar transactions, to advance and accelerate the development and
enhance the commercial potential of its product candidates. For
more information, visit www.arvinas.com.
Arvinas Forward-Looking StatementsThis press
release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995 that involve
substantial risks and uncertainties, including statements regarding
the potential advantages and therapeutic benefits of vepdegestrant
(ARV-471). All statements, other than statements of historical
facts, contained in this press release are forward-looking
statements. The words “believe,” “expect,” “may,” “plan,”
“potential,” “will,” “continue,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
We may not actually achieve the plans, intentions or
expectations disclosed in our forward-looking statements, and you
should not place undue reliance on our forward-looking statements.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements we make as a result of various risks and uncertainties,
including but not limited to: our and Pfizer Inc.’s (“Pfizer”)
performance of our respective obligations with respect to our
collaboration with Pfizer; whether we and Pfizer will be able to
successfully conduct and complete clinical development for
vepdegestrant and obtain marketing approval for and commercialize
vepdegestrant on our current timelines or at all; whether our cash
and cash equivalent resources will be sufficient to fund our
foreseeable and unforeseeable operating expenses and capital
expenditure requirements; and other important factors discussed in
the “Risk Factors” section of our Annual Report on Form 10-K for
the year ended December 31, 2022, and subsequent other reports on
file with the Securities and Exchange Commission. The
forward-looking statements contained in this press release reflect
our current views with respect to future events, and we assume no
obligation to update any forward-looking statements except as
required by applicable law. These forward-looking statements should
not be relied upon as representing our views as of any date after
the date of this release.
Investor Contact:Jeff Boyle, Arvinas Investor
Relations347-247-5089Jeff.Boyle@arvinas.com
Media Contact:Kirsten Owens, Arvinas
Communications203-584-0307Kirsten.Owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Arvinas (NASDAQ:ARVN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024